POTENTIAL IMPACT OF POLICY REGULATION AND GENERIC COMPETITION ON SALES OF CHOLESTEROL LOWERING MEDICATION, ANTIDEPRESSANTS AND ACID BLOCKING AGENTS IN BELGIUM

REFERENCES

• Crott, R., et al., Evolutie van de uitgaven voor gezondheidszorg. 2005, Federaal Kenniscentrum voor de Gezondheidszorg (KCE): Brussels
   Google Scholar
• Health data 2010. 2010, (http://stats.oecd.org)
   Google Scholar
• Danzon, P.M. and J.D. Ketcham, Reference pricing of pharmaceuticals for Medi-care: evidence from Germany, The Netherlands, and New Zealand. Front Health Policy Res 2004; 7: 1–54.
   Google Scholar
• Godman, B., et al., Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics 2009; 27(5): 435–438.
   PubMed Web of Science ®Google Scholar
• Simoens, S. and S. De Coster, Sustaining generic medicines markets in Europe. Research centre for pharmaceutical care and pharmacoeconomics, Katholieke Universiteit Leuven (KUL), Leuven, April 2006; 103.
   Google Scholar
• Stargardt, T., The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur J Health Econ 2010; 11(3): 267–277.
   Web of Science ®Google Scholar
• Simoens, S., Interchangeability of off-patent medicines: a pharmacoeconomic perspective. Expert Rev Pharmacoecon Outcomes Res 2008; 8(6): 519–521.
   Google Scholar
• European Generic Medicines Association (EGA), Generic market shares in Europe 2006. 2007, (http://www.egagenerics.com/doc/fac-GxMktEur_2006.pdf)
   Google Scholar
• Magazzini, L., F. Pammolli, and M. Riccaboni, Dynamic competition in pharma-ceuticals. Patent expiry, generic penetration, and industry structure. EurJ Health Econ 2004; 5(2): 175–182.
   PubMedGoogle Scholar
• Frank, R. and D. Salkever, Generic entry and the pricing of pharmaceuticals. J Econ Manage Strat 1997; 6(1): 75–90.
   Web of Science ®Google Scholar
• Kong, Y., Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical. Health Econ 2009; 18(5): 591–606.
   Web of Science ®Google Scholar
• Lexchin, J., The effect of generic competition on the price of brand-name drugs. Health Policy 2004; 68(1): 47–54.
   PubMed Web of Science ®Google Scholar
• Suh, D.C., et al., Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Serv Res 2000; 35(2): 529–547.
   PubMed Web of Science ®Google Scholar
• Ferrandiz, J.M., The impact of generic goods in the pharmaceutical industry. Health Econ 1999; 8(7): 599–612.
   Web of Science ®Google Scholar
• Hollis, A., How do brands'"own generics" affect pharmaceutical prices? Rev Ind Organ 2005; 27: 329–350.
   Web of Science ®Google Scholar
• Pavenik, N., Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Rand J Econ 2002; 33(3): 469–487.
   PubMed Web of Science ®Google Scholar
• Seeley, E. and P. Kanavos, Generic medicines from a societal perspective. Sav-ings for health care systems? Eurohealth 2008; 14(2): 18–22.
   Google Scholar
• Puig-Junoy, J., The impact of generic reference pricing interventions in the sta-tin market. Health Policy 2007; 84(1): 14–29.
   Web of Science ®Google Scholar
• Puig-Junoy, J., Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics 2010; 28(8): 649–663.
   PubMed Web of Science ®Google Scholar
• Andersson, K.A., et al., Influence of mandatory generic substitution on pharma-ceutical sales patterns: a national study over five years. BMC Health Serv Res 2008; 8: 50.
   PubMed Web of Science ®Google Scholar
• Ess, S.M., S. Schneeweiss, and T.D. Szucs, European healthcare policies for con-trolling drug expenditure. Pharmacoeconomics 2003; 21(2): 89–103.
   PubMed Web of Science ®Google Scholar
• De Graeve, D., et al., Eigen betalingen in de Belgische gezondheidszorg. De impact van supplementen. 2006, Federaal Kenniscentrum voor de Gezond-heidszorg (KCE): Brussel
   Google Scholar
• Labelle, R., G. Stoddart, and T. Rice, A re-examination of the meaning and importance of supplier-induced demand. J Health Econ 1994; 13(3): 347–368.
   PubMed Web of Science ®Google Scholar
• Farmaceutische kengetallen 2007; 2010, RIZIV/INAMI: Brussel
   Google Scholar
• Simoens, S., et al., Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 2005; 23(8): 755–766.
   PubMed Web of Science ®Google Scholar
• Pedersen, T., et al., Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). The Lancet 1994; 344: 1383–1389.
   PubMed Web of Science ®Google Scholar
• Chen, Y., et al., Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res Social Adm Pharm 2008; 4(3): 244–257.
   PubMed Web of Science ®Google Scholar
• Dylst, P and S. Simoens, Does the market share of generic medicines influ-ence the price level? A European analysis. Pharmacoeconomics 2011; 29(10): 875–882.
   PubMed Web of Science ®Google Scholar
• Dylst, P. and S. Simoens, Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals 2010; 3:471–481.
   Google Scholar
• Dylst, P., A. Vulto, and S. Simoens, Tendering for outpatient prescription phar-maceuticals: What can be learned from current practices in Europe? Health Policy, 2011.
   Web of Science ®Google Scholar
• IMS Health, Top 15 global products, 2009, total audited markets. 2009, (http://www.imshealth.com)
   Google Scholar
• Wettermark, B., et al., Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy 2009; 7(3): 137–147.
   PubMedGoogle Scholar
• Gonzalez, J., et al., Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. Int J Res Mark 2008; 25(4): 247–260.
   Web of Science ®Google Scholar
• Godman, B., et al., Policies to enhance prescribing efficiency in Europe: Findings and future implications. Front Pharmacology 2011; 1(141).
   PubMed Web of Science ®Google Scholar
• Godman, B., et al., Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implica-tions. Expert Rev Pharmacoecon Outcomes Res. 10(6): 707–722.
   Google Scholar
• Granlund, D., Price and welfare effects of a pharmaceutical substitution reform. J Health Econ. 29(6): 856–865.
   Web of Science ®Google Scholar
• Voorschrijven op stofnaam. Voorstellen voor de praktische toepassing in de medische praktijk en in het elektronisch medisch dossier. maart 2010, Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI): Brussel
   Google Scholar
• Ferner, R., W. Lenney, and J. Marriot, Controversy over generic substitution. BMJ 2010; 340(c2548): 1341–1343.
   Google Scholar
• Moon, J.C., et al., Getting better value from the NHS drug budget. BMJ. 341:c6449.
   Google Scholar